Cipremi (Remdesivir Injection)
Active ingredient: Remdesivir
Manufacturer : Cipla
Product Code: Remdes-Cipla
Cipremi is out of stock, please send a ticket and we will let you know when it will be available for purchase.
Cipremi (REMDESIVIR) What Is It?
Remdesivir is an antiviral drug that is approved for emergency use for coronavirus disease
2019 (COVID-19). The drug is in the process of being studied but has shown reduced
recovery time in certain people. Limited information is available for the safety and efficacy
of this antiviral at this time. The United States FDA has authorized the use of remdesivir
under emergency conditions as it meets specific criteria for performance, safety, and
labeling. This emergency use authorization (EUA) is effective for the duration of COVID-19 or
until the EUA is terminated or revoked, and the drug will no longer be used after that.
Cipremi (REMDESIVIR) - Classification and Mechanism of Action
Remdesivir belongs to the class of antimetabolites and is a prodrug of an analog of
Remdesivir is broken down in the body and converted to its active form, which acts on the
viral RNA (genetic material) and negatively affects the replication of the virus.
Looking After Cipremi
preparation that has been diluted for administration should be stored for up to
four hours at room temperature, 20 o C to 25 o C (68 o F to 77 o F), or up to 24 hours at
refrigerated temperature, 2 o C to 8 o C (36 o F to 46 o F).
How to Take Cipremi (Remdesivir Injection)
Remdesivir is usually administered through a vein (intravenously [IV]) once a day for up to
10 days based on your doctor’s advice.
Dosage and How Long Should You Take It
The recommended dosage of remdesivir is as follows:
In adults, IV administration of a single dose of 200 mg should be done on the first
day, after which a maintenance dose of 100 mg once per day should be given.
If the individual requires a ventilator, treatment is recommended for 10 days. If
ventilation is not needed, treatment generally should last for five days; however, if
improvement is not observed after five days, treatment for an additional five days (a
total of 10 days) may be given.
In children with a body weight between 3.5 kg to less than 40 kg, remdesivir should
be given as an injection at a dose of 5 mg/kg on day 1. From day 2, a dose of 2.5
mg/kg should be given. In children weighing more than 40 kg, the dosage is the same
as that for adults.
There are no reports of an overdose of remdesivir; however, if the need arises, the
treatment for overdose includes monitoring vital signs such as blood pressure and pulse and
checking the individual’s clinical status. No specific antidote for remdesivir is available.
Warnings and Precautions
Before starting treatment with remdesivir, inform your doctor if you:
Are allergic to remdesivir or any of the ingredients in the preparation or other
Are breastfeeding, pregnant, or plan to become pregnant
Are taking any prescription or non-prescription medications, especially chloroquine
or hydroxychloroquine, or supplements.
Have or have had any kidney or liver disease
Possible Side Effects
Some of the possible side effects of Cipremi (Remdesivir Injection) are as follows:
Allergies that may show symptoms like:
Change in heartbeat
Low blood pressure
Swelling on the lips, face, or throat
Shortness of breath
Increased levels of liver enzymes, which are monitored before and on all the days
the drug is administered
All the side effects of remdesivir are not known yet as remdesivir is still being studied, and
serious side effects are possible.
The following side effects of taking IV medicines may occur at the injection site:
Remdesivir was a key contender as a therapeutic agent for COVID-19 because it showed
activity against severe acute respiratory syndrome coronavirus and Middle East respiratory
syndrome coronavirus. A trial by Beigel et al. was conducted to evaluate the efficacy of
remdesivir for COVID-19 compared to placebo. In the study, it was seen that individuals who
were administered remdesivir recovered in 11 days, on an average, compared to 15 days in
other individuals. Remdesivir was seen to be the most beneficial in people who required
1. U.S. FDA. Fact sheet for patients and parents/caregivers emergency use
authorization (EUA) of remdesivir for coronavirus disease 2019 (COVID-19) [Internet]
[Updated Jun 2020]. Available at: https://www.fda.gov/media/137565/download.
Accessed on Jul 1, 2020.
2. PubChem. Remdesivir [Internet]. Available at:
Interactions. Accessed on Jul 1, 2020.
3. U.S. FDA. Fact sheet for health care providers emergency use authorization (EUA) of
remdesivir (GS-5734™) [Internet] [Updated Jun 2020]. Available at:
https://www.fda.gov/media/137566/download. Accessed on Jul 1, 2020.
4. MedlinePlus. Remdesivir injection [Internet] [Updated Jun 15, 2020]. Available at:
https://medlineplus.gov/druginfo/meds/a620033.html. Accessed on Jul 1, 2020.
5. Beigel JH, et al. Remdesivir for the treatment of Covid-19 — Preliminary report. N
Engl J Med. 2020 May 22;NEJMoa2007764. doi: 10.1056/NEJMoa2007764. Online
ahead of print. Available at: